vs
ROCKY BRANDS, INC.（RCKY）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
ROCKY BRANDS, INC.的季度营收约是再鼎医药的1.1倍（$139.7M vs $127.1M），再鼎医药同比增速更快（17.1% vs 9.1%），ROCKY BRANDS, INC.自由现金流更多（$16.7M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 11.2%）
洛基品牌公司（原洛基鞋靴公司）1932年创立于俄亥俄州纳尔逊维尔，总部至今仍设于该地。公司主营户外、工装、西部风格及军用鞋靴的设计研发、生产与销售，同时也推出各类户外与工装服饰及周边配件。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
RCKY vs ZLAB — 直观对比
营收规模更大
RCKY
是对方的1.1倍
$127.1M
营收增速更快
ZLAB
高出8.0%
9.1%
自由现金流更多
RCKY
多$43.4M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
11.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $139.7M | $127.1M |
| 净利润 | $6.5M | — |
| 毛利率 | 41.3% | 51.0% |
| 营业利润率 | 6.9% | -54.6% |
| 净利率 | 4.7% | — |
| 营收同比 | 9.1% | 17.1% |
| 净利润同比 | 35.7% | — |
| 每股收益（稀释后） | $0.86 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RCKYZLAB
| Q4 25 | $139.7M | $127.1M | ||
| Q3 25 | $122.5M | $115.4M | ||
| Q2 25 | $105.6M | $109.1M | ||
| Q1 25 | $114.1M | $105.7M | ||
| Q4 24 | $128.1M | $108.5M | ||
| Q3 24 | $114.6M | $101.8M | ||
| Q2 24 | $98.3M | $100.1M | ||
| Q1 24 | $112.9M | $87.1M |
净利润RCKYZLAB
| Q4 25 | $6.5M | — | ||
| Q3 25 | $7.2M | $-36.0M | ||
| Q2 25 | $3.6M | $-40.7M | ||
| Q1 25 | $4.9M | $-48.4M | ||
| Q4 24 | $4.8M | — | ||
| Q3 24 | $5.3M | $-41.7M | ||
| Q2 24 | $-1.2M | $-80.3M | ||
| Q1 24 | $2.5M | $-53.5M |
毛利率RCKYZLAB
| Q4 25 | 41.3% | 51.0% | ||
| Q3 25 | 40.2% | 59.5% | ||
| Q2 25 | 41.0% | 60.6% | ||
| Q1 25 | 41.2% | 63.6% | ||
| Q4 24 | 41.5% | 61.5% | ||
| Q3 24 | 38.1% | 64.1% | ||
| Q2 24 | 38.7% | 64.9% | ||
| Q1 24 | 39.1% | 61.4% |
营业利润率RCKYZLAB
| Q4 25 | 6.9% | -54.6% | ||
| Q3 25 | 9.6% | -42.3% | ||
| Q2 25 | 6.8% | -50.3% | ||
| Q1 25 | 7.6% | -53.3% | ||
| Q4 24 | 6.6% | -62.6% | ||
| Q3 24 | 8.8% | -66.6% | ||
| Q2 24 | 4.6% | -76.0% | ||
| Q1 24 | 7.1% | -80.7% |
净利率RCKYZLAB
| Q4 25 | 4.7% | — | ||
| Q3 25 | 5.9% | -31.2% | ||
| Q2 25 | 3.4% | -37.3% | ||
| Q1 25 | 4.3% | -45.8% | ||
| Q4 24 | 3.7% | — | ||
| Q3 24 | 4.6% | -40.9% | ||
| Q2 24 | -1.3% | -80.2% | ||
| Q1 24 | 2.3% | -61.4% |
每股收益（稀释后）RCKYZLAB
| Q4 25 | $0.86 | $-0.05 | ||
| Q3 25 | $0.96 | $-0.03 | ||
| Q2 25 | $0.48 | $-0.04 | ||
| Q1 25 | $0.66 | $-0.04 | ||
| Q4 24 | $0.65 | $-0.09 | ||
| Q3 24 | $0.70 | $-0.04 | ||
| Q2 24 | $-0.17 | $-0.08 | ||
| Q1 24 | $0.34 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.9M | $689.6M |
| 总债务越低越好 | $122.6M | — |
| 股东权益账面价值 | $252.1M | $715.5M |
| 总资产 | $477.5M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.49× | — |
8季度趋势，按日历期对齐
现金及短期投资RCKYZLAB
| Q4 25 | $2.9M | $689.6M | ||
| Q3 25 | $3.3M | $717.2M | ||
| Q2 25 | $2.8M | $732.2M | ||
| Q1 25 | $2.6M | $757.3M | ||
| Q4 24 | $3.7M | $779.7M | ||
| Q3 24 | $3.7M | $616.1M | ||
| Q2 24 | $4.1M | $630.0M | ||
| Q1 24 | $3.1M | $650.8M |
总债务RCKYZLAB
| Q4 25 | $122.6M | — | ||
| Q3 25 | $139.0M | — | ||
| Q2 25 | $132.5M | — | ||
| Q1 25 | $128.6M | — | ||
| Q4 24 | $128.7M | — | ||
| Q3 24 | $150.3M | — | ||
| Q2 24 | $152.4M | — | ||
| Q1 24 | $156.0M | — |
股东权益RCKYZLAB
| Q4 25 | $252.1M | $715.5M | ||
| Q3 25 | $246.1M | $759.9M | ||
| Q2 25 | $239.1M | $791.7M | ||
| Q1 25 | $236.2M | $810.8M | ||
| Q4 24 | $232.2M | $840.9M | ||
| Q3 24 | $228.3M | $667.7M | ||
| Q2 24 | $223.8M | $704.2M | ||
| Q1 24 | $225.3M | $762.2M |
总资产RCKYZLAB
| Q4 25 | $477.5M | $1.2B | ||
| Q3 25 | $494.0M | $1.2B | ||
| Q2 25 | $471.0M | $1.2B | ||
| Q1 25 | $468.2M | $1.2B | ||
| Q4 24 | $457.3M | $1.2B | ||
| Q3 24 | $475.0M | $985.3M | ||
| Q2 24 | $467.9M | $987.4M | ||
| Q1 24 | $466.5M | $988.4M |
负债/权益比RCKYZLAB
| Q4 25 | 0.49× | — | ||
| Q3 25 | 0.57× | — | ||
| Q2 25 | 0.55× | — | ||
| Q1 25 | 0.54× | — | ||
| Q4 24 | 0.55× | — | ||
| Q3 24 | 0.66× | — | ||
| Q2 24 | 0.68× | — | ||
| Q1 24 | 0.69× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.6M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $16.7M | $-26.7M |
| 自由现金流率自由现金流/营收 | 12.0% | -21.0% |
| 资本支出强度资本支出/营收 | 0.6% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.70× | — |
| 过去12个月自由现金流最近4个季度 | $9.7M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流RCKYZLAB
| Q4 25 | $17.6M | $-26.0M | ||
| Q3 25 | $-3.3M | $-32.0M | ||
| Q2 25 | $812.0K | $-31.0M | ||
| Q1 25 | $1.2M | $-61.7M | ||
| Q4 24 | $24.4M | $-55.8M | ||
| Q3 24 | $4.5M | $-26.8M | ||
| Q2 24 | $6.5M | $-42.2M | ||
| Q1 24 | $17.4M | $-90.1M |
自由现金流RCKYZLAB
| Q4 25 | $16.7M | $-26.7M | ||
| Q3 25 | $-5.2M | $-35.0M | ||
| Q2 25 | $-2.4M | $-33.9M | ||
| Q1 25 | $529.0K | $-63.2M | ||
| Q4 24 | $22.9M | $-58.4M | ||
| Q3 24 | $3.5M | $-28.2M | ||
| Q2 24 | $4.6M | $-42.9M | ||
| Q1 24 | $17.1M | $-91.1M |
自由现金流率RCKYZLAB
| Q4 25 | 12.0% | -21.0% | ||
| Q3 25 | -4.2% | -30.4% | ||
| Q2 25 | -2.2% | -31.1% | ||
| Q1 25 | 0.5% | -59.9% | ||
| Q4 24 | 17.9% | -53.8% | ||
| Q3 24 | 3.0% | -27.7% | ||
| Q2 24 | 4.7% | -42.9% | ||
| Q1 24 | 15.2% | -104.5% |
资本支出强度RCKYZLAB
| Q4 25 | 0.6% | 0.5% | ||
| Q3 25 | 1.5% | 2.6% | ||
| Q2 25 | 3.0% | 2.6% | ||
| Q1 25 | 0.6% | 1.5% | ||
| Q4 24 | 1.2% | 2.4% | ||
| Q3 24 | 0.9% | 1.3% | ||
| Q2 24 | 1.9% | 0.7% | ||
| Q1 24 | 0.2% | 1.1% |
现金转化率RCKYZLAB
| Q4 25 | 2.70× | — | ||
| Q3 25 | -0.46× | — | ||
| Q2 25 | 0.23× | — | ||
| Q1 25 | 0.25× | — | ||
| Q4 24 | 5.08× | — | ||
| Q3 24 | 0.85× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 6.82× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RCKY
| Wholesale | $79.6M | 57% |
| Retail1 | $57.0M | 41% |
| Contract Manufacturing | $3.2M | 2% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
